BACKGROUND: Cardiac rhabdomyoma (CRs) are the most common primary tumour of the heart in infants and children. Usually are multiple and, basing on the location can cause a haemodynamic disturbance, dysrhythmias or heart failure during the fetal and early postnatal period. CRs have a natural history of spontaneous regression and are closely associated with tuberous sclerosis complex (TSC). It has an association with tuberous sclerosis (TS), and in those, the tumour may regress and disappear completely, or remain consistent in size.
Introduction
In 1982, DeVore et al. first reported the prenatal diagnosis of a cardiac tumour. With the advancement of fetal echocardiography and magnetic resonance imaging (MRI), prenatal diagnosis of fetal cardiac tumours has become feasible, and the number of case series reported has increased in this past decade [1] .
With the estimated incidence 1 in 20,000 births are the most common fetal cardiac tumour. Cardiac rhabdomyoma CRs) are often multiple and can represent up to 90% of cardiac tumours in the paediatric population 1. The majority are diagnosed during the fetal period or before the age of 1 year. CRs diagnosed on fetal echocardiography are typical of TSC [2] . It may be isolated or associated with other specific lesions of TSC, namely cortical tubers and subependymal nodules, or, rarely, renal lesions. The association of CR with such specific lesions during fetal life strongly supports the diagnosis of TSC [2, 3] . As cerebral lesions are responsible for the most severe clinical manifestations of the disease, such as seizures, mental retardation and behavioural abnormalities, the neurodevelopmental outcome is a critical issue when cerebral lesions are observed during fetal life. The absence of a brain or renal lesions, however, excludes neither the diagnosis of TSC nor the possibility of future neurodevelopmental complications, because lesions may develop progressively after birth [3, 4] . Tuberous sclerosis complex is an autosomal dominant genetic disease with an incidence of about 1/6000 to 1/10 000 live births. It is characterised by the widespread development of hamartomas in different tissues. It is caused by mutations in either the TSC1 or the TSC2 gene, located on chromosomes 9q34 and 16p13.3, respectively [5] . http://www.mjms.mk/ http://www.id-press.eu/mjms/ The exact incidence of rhabdomyoma coexisting with TS in fetuses is unknown; although an estimate of one in 10 000 in routine necropsies of all ages was reported. With improved sonographic, MRI and molecular analytical technology, a fetal diagnosis of cardiac rhabdomyoma may be of great clinical significance [3, 6] .
The purpose of this meta-analysis, with the addition of 12 cases from our hospital, was to evaluate outcome in cases diagnosed with fetal cardiac rhabdomyoma using prenatal sonography.
Study design
We reviewed the medical records of all cases diagnosed prenatally by fetal echocardiography, with cardiac rhabdomyoma, between January 2010 and December 2016.
Results
Twelve fetuses with cardiac rhabdomyoma were diagnosed at 21.4 ± 6.0 weeks' gestational age. Of ten continued pregnancies, there were two spontaneous intrauterine deaths, in 8 cases termination of pregnancies was chosen by parents and four were delivered at term. Although, of continuing pregnancies, none had prenatal hemodynamic complications, after birth none had cardiac symptoms. Over the same period, all patients were diagnosed with cardiac rhabdomyoma postnatally. All were referred for cardiac assessment after findings suggesting TSC. On follow-up, TSC was confirmed in all patients including neurodevelopmental disease. The incidence of cardiac symptoms and TSC was not statistically different between the prenatal and postnatal diagnosis groups.
The demographics of the 12 cases of fetal cardiac rhabdomyoma from our hospital are shown in Table 1 . There were nine cases with multiple tumours (Figure 1 and 2 ) and three cases with single tumours (Figure 3 ). The mean diameter of the tumour mass at detection was 17 (range, 6-29) mm. Seven cases of cardiac rhabdomyoma were detected before 20 weeks of gestation. Of the four surviving neonates, all were associated with TS, and all had multiple tumours. There was no survivor when fetal hydrops or fetal dysrhythmia occurred. 
Discussion
Cardiac rhabdomyoma are the most common fetal cardiac tumours during prenatal and neonatal periods, accounting for 60-86% of primary fetal cardiac tumours. Prenatally, they are usually diagnosed during the second or third trimester [6, 7] .
On ultrasound, rhabdomyomas appear as round, homogeneous, hyperechogenic masses in the ventricles, and they sometimes appear as multiple foci in the ventricles and septal wall. Differential diagnosis between rhabdomyoma, fibroma or myxoma using ultrasonography for a single cardiac mass remains difficult.
Figure 3: Fetus in the 26th gestational week of pregnancy with multiple rhabdomyoma
On the contrary, other primary cardiac tumours in fetuses such as teratoma and hemangioma are easily distinguishable, both clinically and using imaging studies. Hemangiomas show a more complex echogenicity, with cystic and solid parts mixed with calcifications, and are usually found in the right atrium. Teratomas are extracardiac masses that are located in the pericardial cavity, always associated with pericardial effusion and weakly associated with TS. Cardiac complications are rare and mainly involve fetal dysrhythmia (brady or tachyarrhythmia), but other complications such as intracardiac obstruction and cardiac failure also may be associated [8] [9] [10] .
The earliest antenatal sonographic detection of a cardiac tumour in our study was at 17 weeks of gestation whereas half of them were detected after 20 weeks of gestations.
The smallest detectable tumour mass was 6 mm, and the largest was 29 mm in diameter. Although the difference was not statistically significant, smaller tumours tended to be multiple and a search for more tumours when the cardiac mass size is small is therefore recommended. In our study, all cardiac rhabdomyoma showed an increase in size in utero, but rapid growth was uncommon. Both foetuses with perinatal death had the tumour mass bigger than ≥ 20 mm in diameter. Although histologically benign, larger tumours carry a greater risk of causing hemodynamic disturbances and dysrhythmias, which could result in poorer outcome at the fetal age [8, 10, 11] .
In our cases, we didn't find cardiac or extracardiac structural defects. Also, there was no any coexistence of cardiac rhabdomyoma with trisomy 21 or any other chromosomal anomalies.
CRs may have different presentations and clinical course. Surgery is only necessary when a hemodynamically significant obstruction is present [12] .
As CRs are associated with long-term development of TSC and other diagnostic features are not yet typically apparent in the prenatal and neonatal periods, careful evaluation and follow-up are essential to exclude TSC [13] .
The genetic basis of TS is heterogeneous, and TS may be caused by the mutation of the tumour suppressor genes TSC1 or TSC2. A genetic method of screening for TS patients has not been established. Cardiac rhabdomyoma may be the earliest sign of TS in utero and precede the detection of brain or kidney lesions. TS follows an autosomal dominant hereditary pattern with variable expression, and 50-80% of childhood cases are considered to result from spontaneous mutations. The detection of cardiac tumours, which can be achieved using prenatal echocardiography, should be used as a warning sign for TS during the counselling of at-risk families [2, 3, 9] .
Despite the aforementioned limitations on the number of cases and lac of MRI investigations, this report showed that a positive family history of TS and multifocality of fetal cardiac rhabdomyoma are two strong predictors of neonatal outcome. Large tumours, hydrops and fetal dysrhythmias are usually correlated with hemodynamic disturbances, resulting in poor outcomes during the fetal life. Fetal echocardiography is useful in the detection of cardiac rhabdomyoma, providing a clue for the detection of TS.
To better predict neurodevelopmental prognosis, further investigation is required to evaluate the number, size and location of specific cerebral lesions in cases that are diagnosed prenatally with CR.
